MK-677 (Ibutamoren)
Scientific Overview MK-677 ibutamoren
MK-677, also known as ibutamoren, MK-0677, or L-163,191, is an orally active, non-peptide growth hormone secretagogue investigated for its effects on the growth hormone (GH) and insulin-like growth factor 1 (IGF-1) signaling axis.
Unlike peptide-based growth hormone-releasing peptides (GHRPs), ibutamoren is a small-molecule compound. It has been investigated in preclinical and clinical research, although it is not an FDA-approved medication.
Mechanism of Action MK-677 ibutamoren
MK-677 acts as an agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), commonly known as the ghrelin receptor. Activation of this G-protein-coupled receptor stimulates growth hormone release and can influence circulating IGF-1 concentrations.
Research involving ibutamoren has examined endocrine signaling, metabolic regulation, and changes in body composition. The magnitude and significance of these effects depend on the experimental model, study population, and study design.
Research Findings MK-677 ibutamoren
Published research provides evidence that MK-677 can influence growth hormone secretion and related biological markers.
In an eight-week randomized, placebo-controlled study involving 24 obese adult men, researchers observed increases in growth hormone-related measures, IGF-1, and fat-free mass. The study also reported impaired glucose homeostasis during oral glucose tolerance testing.
Other research has examined bone-turnover markers following short-term exposure. Changes in these markers do not, by themselves, establish improved bone strength or reduced fracture risk.
These findings describe specific published studies and should not be interpreted as proof of the identity, purity, performance, or suitability of any separately supplied research material.
Research Applications
Areas investigated in the scientific literature include:
- Growth hormone secretion and endocrine signaling
- Ghrelin receptor pharmacology
- G-protein-coupled receptor signaling
- Growth hormone and IGF-1 axis research
- Bone turnover and mineral metabolism
- Body composition research
- Glucose homeostasis and insulin sensitivity
- Energy balance and metabolic regulation
- Sleep and circadian physiology
These are research topics, not established therapeutic indications for this material.
Laboratory Handling and Limitations
This material is designated solely for lawful in vitro and other nonclinical laboratory research where permitted. It is not intended for human or veterinary use, consumption, administration, diagnosis, or treatment.
Laboratory Handling MK-677 ibutamoren
Qualified laboratory personnel should follow applicable institutional procedures, relevant safety documentation, suitable personal protective equipment requirements, and verified storage instructions.
Researchers are responsible for appropriate experimental controls, material verification, waste disposal, and compliance with applicable laws and institutional requirements.
Research Limitations
Published studies of ibutamoren do not establish the identity, composition, purity, stability, or performance of a particular supplier’s material. Those properties require appropriate product-specific documentation and analytical verification.
The available evidence also does not establish long-term safety or prove that findings from specific study populations apply to other populations or experimental systems.
Safety and Regulatory Considerations
Ibutamoren is not approved by the US Food and Drug Administration as a medication. The FDA has identified potential safety concerns, including changes in glucose metabolism, fluid retention, increased appetite, and a potential risk of congestive heart failure in certain individuals.
These concerns are important when evaluating the published literature and the regulatory status of ibutamoren. Research findings should not be used as a substitute for medical advice or as evidence that the compound is safe for human use.
Scientific References
- Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. The Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362–369. https://doi.org/10.1210/jcem.83.2.4539
- Svensson J, Ohlsson C, Jansson JO, et al. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males. Journal of Bone and Mineral Research. 1998;13(7):1158–1166. https://doi.org/10.1359/jbmr.1998.13.7.1158
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Reviews
There are no reviews yet.